H. Gatanaga

S. Oka, N. Tachikawa, H. Gatanaga, 2000, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Reply to Tattevin et al.

S. Oka, H. Gatanaga, H. Komatsu, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Trends in early and late diagnosis of HIV-1 infections in Tokyoites from 2002 to 2010.

S. Oka, H. Gatanaga, Y. Kikuchi, 2012, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Successful treatment for Kaposi sarcoma inflammatory cytokine syndrome in a severe CD4+ lymphocytopenic HIV patient.

S. Oka, Yasuaki Yanagawa, Koji Watanabe, 2019, AIDS.

Low Raltegravir Concentration in Cerebrospinal Fluid in Patients With ABCG2 Genetic Variants

S. Oka, H. Gatanaga, Tsunefusa Hayashida, 2014, Journal of acquired immune deficiency syndromes.

Raltegravir can be used safely in HIV-1-infected patients treated with warfarin

H. Yazaki, S. Oka, K. Tsukada, 2012, International journal of STD & AIDS.

Favourable use of non-boosted fosamprenavir in patients treated with warfarin

S. Oka, K. Tsukada, H. Gatanaga, 2009, International journal of STD & AIDS.

Dyslipidemia and cardiovascular disease in Vietnamese people with HIV on antiretroviral therapy.

N. V. Trung, S. Oka, N. T. Dung, 2020, Global health & medicine.

Raltegravir-associated perihepatitis and peritonitis: a single case report.

S. Oka, K. Tsukada, H. Gatanaga, 2010, AIDS.

5. Feaure and the Usage of New Integrase Inhibitor CCR5 Antagonistic Agent

H. Gatanaga, 2009 .

Clinical characteristics and prognosis of immunosuppressed inpatients with COVID-19 in Japan

H. Ohtsu, N. Ohmagari, Y. Asai, 2021, Journal of Infection and Chemotherapy.

Prophylactic effect of antiretroviral therapy on hepatitis B virus infection.

S. Oka, H. Gatanaga, J. Tanuma, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

4′-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro

M. Matsuoka, H. Mitsuya, H. Gatanaga, 2001, Antimicrobial Agents and Chemotherapy.

Detection of Toxoplasma gondii, Epstein-Barr virus, and JC virus DNAs in the cerebrospinal fluid in acquired immunodeficiency syndrome patients with focal central nervous system complications.

S. Oka, N. Tachikawa, A. Iwamoto, 1999, Internal medicine.

Successful genotype-tailored treatment with small-dose efavirenz.

S. Oka, H. Gatanaga, 2009, AIDS.

Dilated cardiomyopathy in an adult human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen.

S. Oka, M. Hiroe, H. Gatanaga, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele

S. Oka, H. Gatanaga, M. Takiguchi, 2022, Journal of virology.

Modified Dynabeads Method for Enumerating CD4+ T-Lymphocyte Count for Widespread Use in Resource-Limited Situations

S. Oka, H. Gatanaga, M. Honda, 2005, Journal of acquired immune deficiency syndromes.

Effectiveness of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy.

S. Oka, N. Tachikawa, H. Gatanaga, 2007, Internal medicine.

Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

S. Oka, N. Tachikawa, T. Shirasaka, 2004, Biochemical and Biophysical Research Communications - BBRC.

Serum (1-->3) beta-D-glucan as a noninvasive adjunct marker for the diagnosis of Pneumocystis pneumonia in patients with AIDS.

H. Yazaki, S. Oka, K. Tsukada, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Underestimated Amoebic Appendicitis among HIV-1-Infected Individuals in Japan

S. Oka, T. Nozaki, M. Kaku, 2016, Journal of Clinical Microbiology.

This information is current as Dendritic Cells Enriched Populations of HIV-Infected Proliferation and IL-2 Production by Highly T Cell + Decreased Stimulation of CD 4

M. Connors, H. Mitsuya, A. Blauvelt, 2003 .

Association between a naturally arising polymorphism within a functional region of HIV-1 Nef and disease progression in chronic HIV-1 infection

T. Miura, S. Oka, A. Iwamoto, 2015, Archives of Virology.

Tenofovir disoproxil fumarate co-administered with lopinavir/ritonavir is strongly associated with tubular damage and chronic kidney disease.

N. V. Trung, S. Oka, N. van Kinh, 2018, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Increase of the adenallene anti-HIV activity in cell culture using its bis(tBuSATE) phosphotriester derivative.

H. Mitsuya, J. Imbach, A. Aubertin, 2002, Bioorganic & medicinal chemistry letters.

Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection

N. Enomoto, M. Honda, S. Kaneko, 2016, Gut.

Distinct expression of Kaposi’s sarcoma‐associated herpesvirus‐encoded proteins in Kaposi’s sarcoma and multicentric Castleman’s disease

S. Oka, T. Sata, Yuko Sato, 2006, Pathology international.

Immunological Control of HIV-1 Disease Progression by Rare Protective HLA Allele

S. Oka, H. Gatanaga, M. Takiguchi, 2022, Journal of virology.

Deconvoluting the Composition of Low-Frequency Hepatitis C Viral Quasispecies: Comparison of Genotypes and NS3 Resistance-Associated Variants between HCV/HIV Coinfected Hemophiliacs and HCV Monoinfected Patients in Japan

W. Sugiura, S. Oka, K. Koike, 2015, PloS one.

Ultrasensitive method to quantify intracellular zidovudine mono-, di- and triphosphate concentrations in peripheral blood mononuclear cells by liquid chromatography-tandem mass spectrometry.

S. Oka, H. Gatanaga, Y. Kikuchi, 2015, Journal of mass spectrometry : JMS.

Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma

H. Mitsuya, S. Oka, K. Maeda, 2021, Scientific Reports.

Amebiasis in HIV-1-Infected Japanese Men: Clinical Features and Response to Therapy

S. Oka, T. Nozaki, Koji Watanabe, 2011, PLoS neglected tropical diseases.

Safety and efficacy of reduced-dose pentamidine as second-line treatment for HIV-related pneumocystis pneumonia.

S. Oka, H. Gatanaga, K. Teruya, 2020, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

A haplotype of the human CXCR1 gene protective against rapid disease progression in HIV-1+ patients

S. Heath, M. Lathrop, F. Matsuda, 2007, Proceedings of the National Academy of Sciences.

Case Report: Hemophagocytic Lymphohistiocytosis Caused by Disseminated Histoplasmosis in a Venezuelan Patient with HIV and Epstein-Barr Virus Reactivation Who Traveled to Japan.

S. Oka, Y. Miyazaki, M. Nagi, 2019, The American journal of tropical medicine and hygiene.

Cytomegalovirus (CMV) retinitis and CMV antigenemia as a clue to impaired adrenocortical function in patients with AIDS

S. Oka, C. Morimoto, Tetsuya Nakamura, 1997, AIDS.

High-risk status of HIV-1 infection in the very low epidemic country, Mongolia, 2007

S. Oka, A. Hachiya, H. Gatanaga, 2009, International journal of STD & AIDS.

Effects of low HIV type 1 load and antiretroviral treatment on IgG-capture BED-enzyme immunoassay.

S. Oka, H. Gatanaga, J. Tanuma, 2008, AIDS research and human retroviruses.

Pharmacogenetic information derived from analysis of HLA alleles.

S. Oka, H. Gatanaga, H. Honda, 2008, Pharmacogenomics.

Diagnostic Utility of Quantitative Plasma Cytomegalovirus DNA PCR for Cytomegalovirus End-Organ Diseases in Patients With HIV-1 Infection

S. Oka, H. Gatanaga, K. Teruya, 2015, Journal of acquired immune deficiency syndromes.

Pathogenesis, clinical course, and recent issues in HIV-1-infected Japanese hemophiliacs: a three-decade follow-up.

S. Oka, K. Tsukada, H. Gatanaga, 2020, Global health & medicine.

Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.

S. Sarafianos, S. Oka, W. Folk, 2013, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

High-performance liquid chromatography-tandem mass spectrometry for simultaneous determination of raltegravir, dolutegravir and elvitegravir concentrations in human plasma and cerebrospinal fluid samples.

S. Oka, H. Gatanaga, K. Tsuchiya, 2018, Biomedical chromatography : BMC.

Influence of Prior HIV-1 Infection on the Development of Chronic Hepatitis B Infection

S. Oka, N. Tachikawa, H. Gatanaga, 2000, European Journal of Clinical Microbiology and Infectious Diseases.

A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

Kwang Su Kim, S. Matsushita, H. Mitsuya, 2019, Cell reports methods.

Blunted fetal growth by tenofovir in late pregnancy.

S. Oka, H. Gatanaga, Y. Kikuchi, 2012, AIDS.

Preemptive Therapy Prevents Cytomegalovirus End-Organ Disease in Treatment-Naïve Patients with Advanced HIV-1 Infection in the HAART Era

S. Oka, K. Tsukada, H. Gatanaga, 2013, PloS one.

High Plasma Concentrations of Zidovudine (AZT) Do Not Parallel Intracellular Concentrations of AZT-Triphosphates in Infants During Prevention of Mother-to-Child HIV-1 Transmission

S. Oka, H. Gatanaga, Y. Kikuchi, 2016, Journal of acquired immune deficiency syndromes.

Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment.

S. Oka, Takao Takahashi, H. Gatanaga, 2007, The Journal of infectious diseases.

Combination of V106I and V179D Polymorphic Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Resistance to Efavirenz and Nevirapine but Not Etravirine

S. Oka, Hironori Sato, H. Ode, 2010, Antimicrobial Agents and Chemotherapy.

Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.

Arun K. Ghosh, J. Wedekind, I. Weber, 2006, Journal of medicinal chemistry.

Rapid and Simple Phenotypic Assay for Drug Susceptibility of Human Immunodeficiency Virus Type 1 Using CCR5-Expressing HeLa/CD4+ Cell Clone 1-10 (MAGIC-5)

S. Oka, A. Kojima, A. Hachiya, 2001, Antimicrobial Agents and Chemotherapy.

Drug-resistant HIV-1 prevalence in patients newly diagnosed with HIV/AIDS in Japan.

W. Sugiura, S. Oka, T. Koike, 2007, Antiviral research.

[Clinical use of anti-HIV agents].

H. Gatanaga, 2007, Nihon yakurigaku zasshi. Folia pharmacologica Japonica.

Impact of Immune Reconstitution-Induced Hepatic Flare on Hepatitis B Surface Antigen Loss in Hepatitis B Virus/Human Immunodeficiency Virus-1 Coinfected Patients

T. Kawaguchi, S. Oka, M. Sugiyama, 2020, The Journal of Infectious Diseases.

Naturally arising HIV-1 Nef variants conferring escape from cytotoxic T lymphocytes influence viral entry co-receptor expression and susceptibility to superinfection.

S. Oka, H. Gatanaga, T. Ueno, 2010, Biochemical and biophysical research communications.

Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors.

S. Oka, M. Kaku, A. Hachiya, 2010, Microbes and infection.

Amino Acid Substitutions in Gag Protein at Non-cleavage Sites Are Indispensable for the Development of a High Multitude of HIV-1 Resistance against Protease Inhibitors*

Hsinyi Tsang, Sek Mardy, Kunio Nagashima, 2002, The Journal of Biological Chemistry.

Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

S. Sarafianos, M. Matsuoka, S. Oka, 2009, Antiviral Research.

Potential for immune-driven viral polymorphisms to compromise antiretroviral-based preexposure prophylaxis for prevention of HIV-1 infection

M. Carrington, M. John, S. Mallal, 2017, AIDS.

Acute Hepatitis C in HIV-1 Infected Japanese Cohort: Single Center Retrospective Cohort Study

S. Oka, Koji Watanabe, K. Tsukada, 2014, PloS one.

Assessment of antigenemia assay for the diagnosis of cytomegalovirus gastrointestinal diseases in HIV-infected patients.

H. Yazaki, S. Oka, J. Akiyama, 2013, AIDS patient care and STDs.

Comment on: Tenofovir DF/emtricitabine/rilpivirine as HIV post-exposure prophylaxis: results from a multicentre prospective study.

S. Oka, H. Gatanaga, 2019, The Journal of antimicrobial chemotherapy.

Herpesvirus-like DNA sequences in Japanese patients with AIDS-related kaposi's sarcoma

S. Oka, S. Mori, N. Tachikawa, 1996, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Broad Recognition of Circulating HIV-1 by HIV-1-Specific Cytotoxic T-Lymphocytes with Strong Ability to Suppress HIV-1 Replication

S. Oka, H. Gatanaga, M. Takiguchi, 2018, Journal of Virology.

CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome

J. Goedert, M. Carrington, B. Walker, 2019, Nature Immunology.

Viral protein R of human immunodeficiency virus type-1 induces retrotransposition of long interspersed element-1

S. Oka, M. Shimura, T. Okamura, 2013, Retrovirology.

Adaptation of HIV-1 to human leukocyte antigen class I

David Heckerman, John Frater, Rodney Phillips, 2009, Nature.

Impaired ability of Nef to counteract SERINC5 is associated with reduced plasma viremia in HIV-infected individuals

J. Carlson, S. Oka, J. Ohashi, 2020, Scientific Reports.

Epstein-Barr viral load in cerebrospinal fluid as a diagnostic marker of central nervous system involvement of AIDS-related lymphoma.

S. Oka, H. Gatanaga, J. Tanuma, 2013, Internal medicine.

Performance of an enzyme-linked immunosorbent-based serological assay for Entamoeba histolytica: Comparison with an indirect immunofluorescence assay using stored frozen samples.

S. Oka, Yasuaki Yanagawa, Koji Watanabe, 2021, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Utility of the Rapid Antigen Detection Test E. histolytica Quik Chek for the Diagnosis of Entamoeba histolytica Infection in Nonendemic Situations

S. Oka, Yasuaki Yanagawa, Koji Watanabe, 2020, Journal of Clinical Microbiology.

Clinical Features and Gut Microbiome of Asymptomatic Entamoeba histolytica Infection

S. Oka, Yasuaki Yanagawa, Koji Watanabe, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Increases in Entamoeba histolytica Antibody–Positive Rates in Human Immunodeficiency Virus–Infected and Noninfected Patients in Japan: A 10-Year Hospital-Based Study of 3,514 Patients

S. Oka, J. Akiyama, Yasuaki Yanagawa, 2016, The American journal of tropical medicine and hygiene.

Clinical significance of high anti-entamoeba histolytica antibody titer in asymptomatic HIV-1-infected individuals.

S. Oka, Koji Watanabe, H. Gatanaga, 2014, The Journal of infectious diseases.

Higher seroprevalence of Entamoeba histolytica than that of HIV-1 at a voluntary counselling and testing centre in Tokyo

S. Oka, K. Yokoyama, Yasuaki Yanagawa, 2019, bioRxiv.

Asymptomatic intestinal amebiasis in Japanese HIV-1-infected individuals.

S. Oka, Koji Watanabe, H. Gatanaga, 2014, The American journal of tropical medicine and hygiene.

Seroprevalence of Entamoeba histolytica at a voluntary counselling and testing centre in Tokyo: a cross-sectional study

S. Oka, K. Yokoyama, Yasuaki Yanagawa, 2020, BMJ Open.

Short Report: Asymptomatic Intestinal Amebiasis in Japanese HIV-1 – Infected Individuals

S. Oka, Koji Watanabe, H. Gatanaga, 2014 .

Erratum to: Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals

S. Oka, Z. Brumme, C. Brumme, 2015, Retrovirology.

Selection of TI8-8V Mutant Associated with Long-Term Control of HIV-1 by Cross-Reactive HLA-B*51:01–Restricted Cytotoxic T Cells

S. Oka, H. Gatanaga, M. Takiguchi, 2014, The Journal of Immunology.

Cross-Reactive HLA-B * 51 : 01 Long-Term Control of HIV-1 by Selection of TI 8-8 V Mutant Associated with

S. Oka, H. Gatanaga, M. Takiguchi, 2014 .

Naturally selected rilpivirine-resistant HIV-1 variants by host cellular immunity.

W. Sugiura, S. Oka, H. Ode, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Differential Clade-Specific HLA-B*3501 Association with HIV-1 Disease Outcome Is Linked to Immunogenicity of a Single Gag Epitope

Andrew K. Sewell, David Heckerman, Philip J. R. Goulder, 2012, Journal of Virology.

Long-Term Control of HIV-1 in Hemophiliacs Carrying Slow-Progressing Allele HLA-B*5101

P. Goulder, S. Oka, H. Gatanaga, 2010, Journal of Virology.

Altered HIV-1 Gag Protein Interactions with Cyclophilin A (CypA) on the Acquisition of H219Q and H219P Substitutions in the CypA Binding Loop*

Arun K. Ghosh, H. Mitsuya, Yasuhiro Suzuki, 2006, Journal of Biological Chemistry.

Host-Specific Adaptation of HIV-1 Subtype B in the Japanese Population

M. John, S. Mallal, J. Carlson, 2014, Journal of Virology.

Slow Turnover of HIV-1 Receptors on Quiescent CD4+ T Cells Causes Prolonged Surface Retention of gp120 Immune Complexes In Vivo

S. Oka, Yasuhiro Suzuki, N. Tachikawa, 2014, PloS one.

Selection of escape mutant by HLA‐C‐restricted HIV‐1 Pol‐specific cytotoxic T lymphocytes carrying strong ability to suppress HIV‐1 replication

S. Oka, M. Koyanagi, M. Hashimoto, 2011, European journal of immunology.

HLA-A*2402-restricted HIV-1-specific cytotoxic T lymphocytes and escape mutation after ART with structured treatment interruptions.

S. Oka, N. Tachikawa, H. Gatanaga, 2008, Microbes and infection.

T-cell responses to sequentially emerging viral escape mutants shape long-term HIV-1 population dynamics

S. Oka, Z. Brumme, C. Brumme, 2020, PLoS pathogens.

Identification of cross-clade CTL epitopes in HIV-1 clade A/E-infected individuals by using the clade B overlapping peptides.

S. Oka, Koji Watanabe, M. Koyanagi, 2013, Microbes and infection.

Selection and Accumulation of an HIV-1 Escape Mutant by Three Types of HIV-1-Specific Cytotoxic T Lymphocytes Recognizing Wild-Type and/or Escape Mutant Epitopes

S. Oka, H. Gatanaga, M. Takiguchi, 2011, Journal of Virology.

Selection and accumulation of an HIV-1 escape mutant by three 1 types of HIV-1-specific CTLs recognizing wild-type and / or 2 escape mutant epitopes 3 4

Oka, H. Gatanaga, M. Takiguchi, 2011 .

Selection of HLA-B57-associated Gag A146P mutant by HLA-B∗48:01-restricted Gag140-147-specific CTLs in chronically HIV-1-infected Japanese.

S. Oka, M. Koyanagi, H. Gatanaga, 2011, Microbes and infection.

Lack of a significant impact of Gag-Protease-mediated HIV-1 replication capacity on clinical parameters in treatment-naive Japanese individuals

S. Oka, Z. Brumme, C. Brumme, 2015, Retrovirology.

Clinical Control of HIV-1 by Cytotoxic T Cells Specific for Multiple Conserved Epitopes

S. Oka, M. Koyanagi, H. Gatanaga, 2015, Journal of Virology.

Control of HIV-1 by an HLA-B*52: 01-C*12 02 Protective Haplotype

S. Oka, M. Koyanagi, H. Gatanaga, 2017, The Journal of infectious diseases.

Effects of a Single Escape Mutation on T Cell and HIV-1 Co-adaptation.

C. Schönbach, G. Gao, V. Appay, 2016, Cell reports.

Distinct HIV-1 Escape Patterns Selected by Cytotoxic T Cells with Identical Epitope Specificity

M. John, S. Mallal, N. Pfeifer, 2012, Journal of Virology.

Identification of a current hot spot of HIV type 1 transmission in Mongolia by molecular epidemiological analysis.

S. Oka, H. Gatanaga, Tsunefusa Hayashida, 2011, AIDS research and human retroviruses.

PCR detection of human herpesviruses in colonic mucosa of individuals with inflammatory bowel disease: Comparison with individuals with immunocompetency and HIV infection

S. Oka, J. Akiyama, N. Uemura, 2017, PloS one.

Emergence of CXCR4-tropic HIV-1 variants followed by rapid disease progression in hemophiliac slow progressors

S. Oka, H. Gatanaga, Y. Kikuchi, 2017, PloS one.

4-phenylquinoline-8-amine induces HIV-1 reactivation and apoptosis in latently HIV-1 infected cells.

K. Maeda, H. Tamamura, K. Tanimoto, 2022, Biochemical and biophysical research communications.

H. Mitsuya, S. Oka, K. Maeda, 2018, The Journal of Biological Chemistry.

Combination of a Latency-Reversing Agent With a Smac Mimetic Minimizes Secondary HIV-1 Infection in vitro

H. Mitsuya, S. Oka, K. Maeda, 2018, Front. Microbiol..

A Therapeutic Strategy to Combat HIV-1 Latently Infected Cells With a Combination of Latency-Reversing Agents Containing DAG-Lactone PKC Activators

H. Mitsuya, K. Maeda, R. Kariya, 2021, Frontiers in Microbiology.

Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy

S. Oka, Noriko Tanaka, H. Gatanaga, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study

S. Oka, J. Akiyama, R. Niikura, 2018, BMC Cancer.

Comparison of CD4(+) T-cell subset distribution in chronically infected HIV(+) patients with various CD4 nadir counts.

S. Oka, H. Gatanaga, M. Takiguchi, 2010, Microbes and infection.

CD8+ T Cell Cross-Reactivity Profiles and HIV-1 Immune Escape towards an HLA-B35-Restricted Immunodominant Nef Epitope

A. Sewell, John J Miles, S. Oka, 2013, PloS one.

HIV-1 Control by NK Cells via Reduced Interaction between KIR2DL2 and HLA-C∗12:02/C∗14:03.

M. Carrington, Y. Qi, S. Oka, 2016, Cell reports.

Collaboration of a Detrimental HLA-B*35:01 Allele with HLA-A*24:02 in Coevolution of HIV-1 with T Cells Leading to Poorer Clinical Outcomes

S. Rowland-Jones, S. Oka, H. Gatanaga, 2021, Journal of virology.

Prevalence of Anal Human Papillomavirus Infection and Risk Factors among HIV-positive Patients in Tokyo, Japan

S. Oka, K. Tadokoro, J. Akiyama, 2015, PloS one.

Superimposed Epitopes Restricted by the Same HLA Molecule Drive Distinct HIV-Specific CD8+ T Cell Repertoires

G. Gao, V. Appay, Yi Shi, 2014, The Journal of Immunology.

T Cell Repertoires + HIV-Specific CD 8 Same HLA Molecule Drive Distinct Superimposed Epitopes Restricted by the Oka and Masafumi

G. Gao, V. Appay, Yi Shi, 2014 .

Identification of Immunodominant HIV-1 Epitopes Presented by HLA-C*12:02, a Protective Allele, Using an Immunopeptidomics Approach

P. Borrow, S. Oka, Wayne Paes, 2019, Journal of Virology.

Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study

S. Oka, J. Akiyama, R. Niikura, 2018, BMC Cancer.

Role of Escape Mutant-Specific T Cells in Suppression of HIV-1 Replication and Coevolution with HIV-1

S. Oka, H. Gatanaga, M. Takiguchi, 2020, Journal of Virology.

Novel Conserved-region T-cell Mosaic Vaccine With High Global HIV-1 Coverage Is Recognized by Protective Responses in Untreated Infection.

A. McMichael, S. Oka, Bette Korber, 2016, Molecular therapy : the journal of the American Society of Gene Therapy.

Full-Genome Analysis of Hepatitis C Virus in Japanese and Non-Japanese Patients Coinfected With HIV-1 in Tokyo

S. Oka, M. Sugiyama, M. Mizokami, 2019, Journal of acquired immune deficiency syndromes.

Full‐genome analysis of hepatitis C virus in HIV‐coinfected hemophiliac Japanese patients

S. Oka, M. Sugiyama, M. Mizokami, 2020, Hepatology research : the official journal of the Japan Society of Hepatology.

Rilpivirine resistance mutation E138K in HIV-1 reverse transcriptase predisposed by prevalent polymorphic mutations.

W. Sugiura, S. Oka, H. Ode, 2016, The Journal of antimicrobial chemotherapy.

Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance

S. Oka, Hironori Sato, H. Ode, 2010, AIDS.

Decreased Stimulation of CD4+ T Cell Proliferation and IL-2 Production by Highly Enriched Populations of HIV-Infected Dendritic Cells

M. Connors, H. Mitsuya, A. Blauvelt, 2003, The Journal of Immunology.

Effective Suppression of HIV-1 Replication by Cytotoxic T Lymphocytes Specific for Pol Epitopes in Conserved Mosaic Vaccine Immunogens

S. Oka, T. Hanke, H. Gatanaga, 2019, Journal of Virology.

CD8+ T cells specific for conserved, cross-reactive Gag epitopes with strong ability to suppress HIV-1 replication

S. Oka, T. Hanke, H. Gatanaga, 2018, Retrovirology.

Raltegravir and elvitegravir-resistance mutation E92Q affects HLA-B*40:02-restricted HIV-1-specific CTL recognition.

S. Oka, H. Gatanaga, M. Takiguchi, 2014, Microbes and infection.

Effective recognition of HIV-1-infected cells by HIV-1 integrase-specific HLA-B∗4002-restricted T cells.

S. Oka, M. Koyanagi, H. Gatanaga, 2011, Microbes and infection.

Mortality and causes of death in people living with HIV in the era of combination antiretroviral therapy compared with the general population in Japan

S. Oka, K. Tsukada, H. Gatanaga, 2020, AIDS.

Traditional but Not HIV-Related Factors Are Associated with Nonalcoholic Fatty Liver Disease in Asian Patients with HIV-1 Infection

S. Oka, T. Shimbo, Y. Nozaki, 2014, PloS one.

Analysis of the hepatic functional reserve, portal hypertension, and prognosis of patients with human immunodeficiency virus/hepatitis C virus coinfection through contaminated blood products in Japan.

N. Tachikawa, K. Nakao, N. Kokudo, 2014, Transplantation proceedings.

High prevalence of circulating dual-class resistant Mycoplasma genitalium in asymptomatic MSM in Tokyo, Japan

S. Oka, K. Yokoyama, Yasuaki Yanagawa, 2021, JAC-antimicrobial resistance.

Effectiveness of doxycycline 100 mg twice daily for 7 days and azithromycin 1 g single dose for the treatment of rectal Chlamydia trachomatis infection among men who have sex with men.

S. Oka, Yasuaki Yanagawa, Koji Watanabe, 2020, The Journal of antimicrobial chemotherapy.

Modified self-obtained pooled sampling to screen for Chlamydia trachomatis and Neisseria gonorrhoeae infections in men who have sex with men

S. Oka, Yasuaki Yanagawa, Koji Watanabe, 2020, Sexually Transmitted Infections.

High-dose oral amoxicillin plus probenecid is highly effective for syphilis in patients with HIV infection.

S. Oka, H. Gatanaga, K. Teruya, 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Usefulness of Automated Latex Turbidimetric Rapid Plasma Reagin Test for Diagnosis and Evaluation of Treatment Response in Syphilis in Comparison with Manual Card Test: a Prospective Cohort Study

S. Oka, H. Gatanaga, K. Teruya, 2018, Journal of Clinical Microbiology.

Prognosis of ocular syphilis in patients infected with HIV in the antiretroviral therapy era

S. Oka, H. Gatanaga, K. Teruya, 2016, Sexually Transmitted Infections.

Validation of mailed via postal service dried blood spot cards on commercially available HIV testing systems.

S. Oka, H. Gatanaga, Tsunefusa Hayashida, 2021, Global health & medicine.

Cerebral Syphilitic Gumma within 5 Months of Syphilis in HIV-Infected Patient

S. Oka, H. Gatanaga, K. Teruya, 2016, Emerging infectious diseases.

Low Prevalence of Transmitted Drug Resistance of HIV-1 During 2008–2012 Antiretroviral Therapy Scaling up in Southern Vietnam

S. Oka, N. T. Chinh, Koji Watanabe, 2014, Journal of acquired immune deficiency syndromes.

Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections

S. Oka, M. Koyanagi, H. Gatanaga, 2015, Journal of Virology.

Oral administration of the CCR5 inhibitor, maraviroc, blocks HIV ex vivo infection of Langerhans cells within the epithelium.

A. Blauvelt, Y. Koyanagi, K. Moriishi, 2013, The Journal of investigative dermatology.

Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued

S. Oka, H. Gatanaga, Y. Kikuchi, 2017, AIDS.

Isolation and Molecular Characterization of a Nelfinavir (NFV)-Resistant Human Immunodeficiency Virus Type 1 That Exhibits NFV-Dependent Enhancement of Replication

S. Oka, Y. Takebe, Hironori Sato, 2003, Journal of Virology.

Brain magnetic resonance imaging screening is not useful for HIV-1-infected patients without neurological symptoms.

K. Hasuo, S. Oka, T. Tajima, 2014, AIDS research and human retroviruses.

Cooperative contribution of gag substitutions to nelfinavir-dependent enhancement of precursor cleavage and replication of human immunodeficiency virus type-1.

S. Oka, K. Koike, Hironori Sato, 2006, Antiviral research.

In Vivo and in Vitro Researches of Drug-resistant HIV

H. Gatanaga, 2003 .

Clinical symptoms and courses of primary HIV-1 infection in recent years in Japan.

H. Yazaki, S. Oka, K. Tsukada, 2011, Internal medicine.

HIV-1 infection, but not syphilis or HBV infection, is a strong risk factor for anorectal condyloma in Asian population: a prospective colonoscopy screening study.

H. Yazaki, S. Oka, M. Mizokami, 2015, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Pre-infection neutralizing antibodies, Omicron BA.5 breakthrough infection, and long COVID: a propensity score-matched analysis

S. Oka, N. Ohmagari, J. Takeuchi, 2023, medRxiv.

Neutralization activity of IgG antibody in COVID‑19‑convalescent plasma against SARS-CoV-2 variants

S. Oka, Y. Takamatsu, S. Kutsuna, 2023, Scientific Reports.

Drug-induced acute interstitial nephritis mimicking acute tubular necrosis after initiation of tenofovir-containing antiretroviral therapy in patient with HIV-1 infection.

H. Yazaki, S. Oka, H. Gatanaga, 2012, Internal medicine.

Anal human papillomavirus infection and its relationship with abnormal anal cytology among MSM with or without HIV infection in Japan

S. Oka, Yasuaki Yanagawa, Koji Watanabe, 2021, Scientific Reports.

Amino Acid Mutation N348I in the Connection Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Confers Multiclass Resistance to Nucleoside and Nonnucleoside Reverse Transcriptase Inhibitors

S. Sarafianos, M. Matsuoka, S. Oka, 2008, Journal of Virology.

Clinical importance of hyper-beta-2-microglobulinuria in patients with HIV-1 infection on tenofovir-containing antiretroviral therapy.

S. Oka, K. Tsukada, H. Gatanaga, 2014, Journal of acquired immune deficiency syndromes.

Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor.

H. Yazaki, S. Oka, K. Tsukada, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Reversal periods and patterns from drug-resistant to wild-type HIV type 1 after cessation of anti-HIV therapy.

S. Oka, K. Koike, H. Gatanaga, 2007, AIDS research and human retroviruses.

Novel patterns of nevirapine resistance-associated mutations of human immunodeficiency virus type 1 in treatment-naïve patients.

M. Matsuoka, H. Mitsuya, S. Oka, 2004, Virology.

Emergence of Protease Inhibitor Resistance–Associated Mutations in Plasma HIV-1 Precedes That in Proviruses of Peripheral Blood Mononuclear Cells by More Than a Year

S. Oka, H. Gatanaga, K. Tsuchiya, 2003, Journal of acquired immune deficiency syndromes.

Mutations other than 103N in human immunodeficiency virus type 1 reverse transcriptase (RT) emerge from K103R polymorphism under non-nucleoside RT inhibitor pressure.

S. Oka, A. Hachiya, H. Gatanaga, 2006, Virology.

Recent Progress in HIV Drug Resistance Research-From Bench to Bedside-

H. Mitsuya, J. Coffin, W. Sugiura, 2005 .

HIV type 1 V3 variation dynamics in vivo: long-term persistence of non-syncytium-inducing genotypes and transient presence of syncytium-inducing genotypes during the course of progressive AIDS.

S. Oka, Y. Nagai, A. Iwamoto, 1997, AIDS research and human retroviruses.

Arginine insertion and loss of N-linked glycosylation site in HIV-1 envelope V3 region confer CXCR4-tropism

S. Oka, Hironori Sato, H. Ode, 2013, Scientific Reports.

Idiopathic oropharyngeal and esophageal ulcers related to HIV infection successfully treated with antiretroviral therapy alone.

S. Oka, H. Gatanaga, K. Teruya, 2013, Internal medicine.

Antiretroviral therapy alone resulted in successful resolution of large idiopathic esophageal ulcers in a patient with acute retroviral syndrome.

S. Oka, Koji Watanabe, K. Tsukada, 2011, AIDS.

What Triggers a Diagnosis of HIV Infection in the Tokyo Metropolitan Area? Implications for Preventing the Spread of HIV Infection in Japan

S. Oka, H. Gatanaga, Y. Kikuchi, 2015, PloS one.

Illicit Drug Use Is a Significant Risk Factor for Loss to Follow Up in Patients with HIV-1 Infection at a Large Urban HIV Clinic in Tokyo

S. Oka, H. Gatanaga, H. Komatsu, 2013, PloS one.

Trends in transmitted drug-resistant HIV-1 and demographic characteristics of newly diagnosed patients: nationwide surveillance from 2003 to 2008 in Japan.

W. Sugiura, S. Oka, T. Koike, 2010, Antiviral research.

Long-term use of protease inhibitors is associated with bone mineral density loss.

H. Yazaki, S. Oka, Koji Watanabe, 2014, AIDS research and human retroviruses.

Serum CCL17 level becomes a predictive marker to distinguish between mild/moderate and severe/critical disease in patients with COVID-19

M. Sugiyama, M. Mizokami, T. Kano, 2020, Gene.

Serum Lactate Dehydrogenase Level One Week after Admission Is the Strongest Predictor of Prognosis of COVID-19: A Large Observational Study Using the COVID-19 Registry Japan

I. Yokota, S. Konno, N. Ohmagari, 2023, Viruses.

Substantially Higher and Earlier Occurrence of Anti‐Tuberculosis Drug‐Related Adverse Reactions in HIV Coinfected Tuberculosis Patients: A Matched‐Cohort Study

S. Oka, M. Kaku, H. Gatanaga, 2017, AIDS patient care and STDs.

Allele and Genotype Frequencies of Cytochrome P450 2B6 Gene in a Mongolian Population

S. Oka, H. Gatanaga, Tsunefusa Hayashida, 2009, Drug Metabolism and Disposition.

Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals

H. Mitsuya, W. Sugiura, S. Oka, 2021, Scientific Reports.

Correlates of Neutralizing/SARS-CoV-2-S1-binding Antibody Response with Adverse Effects and Immune Kinetics in BNT162b2-Vaccinated Individuals

S. Oka, Y. Takamatsu, Y. Uemura, 2021, medRxiv.

Exploring the genetic diversity of the Japanese population: Insights from a large-scale whole genome sequencing analysis

K. Ozaki, S. Niida, K. Miyo, 2023, bioRxiv.

Efavirenz Enhances HIV-1 Gag Processing at the Plasma Membrane through Gag-Pol Dimerization

F. Momose, Y. Morikawa, H. Gatanaga, 2013, Journal of Virology.

DimerizationPlasma Membrane through Gag-Pol Efavirenz Enhances HIV-1 Gag Processing

F. Momose, Y. Morikawa, H. Gatanaga, 2014 .

Outbreak of Pneumocystis jiroveci Pneumonia in Renal Transplant Recipients: P. jiroveci Is Contagious to the Susceptible Host

H. Yazaki, S. Oka, N. Goto, 2009, Transplantation.

Electrocautery ablation therapy for anal intraepithelial carcinoma: A study protocol

S. Oka, Koji Watanabe, H. Gatanaga, 2022, Medicine.

Control Survey of HIV-1 Genotypic Drug-resistance Testing in Japan

W. Sugiura, S. Oka, T. Koike, 2007 .

Performance and quality assurance of genotypic drug-resistance testing for human immunodeficiency virus type 1 in Japan.

W. Sugiura, S. Oka, T. Koike, 2007, Japanese journal of infectious diseases.

Emergence of raltegravir-resistant HIV-1 in the central nervous system

S. Oka, K. Tsukada, H. Gatanaga, 2010, International journal of STD & AIDS.

Brief Report: High Peak Level of Plasma Raltegravir Concentration in Patients With ABCB1 and ABCG2 Genetic Variants

S. Oka, H. Gatanaga, Tsunefusa Hayashida, 2016, Journal of acquired immune deficiency syndromes.

Unexpected high prevalence of severe coronary artery stenosis in Japanese hemophiliacs living with HIV-1.

Y. Hiroi, S. Oka, H. Gatanaga, 2020, Global health & medicine.

The role of conventional antibodies targeting the CD4 binding site and CD4-induced epitopes in the control of HIV-1 CRF01_AE viruses.

S. Matsushita, T. Yamashiro, H. Gatanaga, 2019, Biochemical and biophysical research communications.

Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men

S. Oka, Yasuaki Yanagawa, Koji Watanabe, 2023, Hepatology.

Prevalence and factors associated with chronic kidney disease and end-stage renal disease in HIV-1-infected Asian patients in Tokyo

S. Oka, K. Tsukada, H. Gatanaga, 2017, Scientific Reports.

Characteristics of Transmitted Drug-Resistant HIV-1 in Recently Infected Treatment-Naive Patients in Japan

W. Sugiura, H. Gatanaga, K. Uchida, 2016, Journal of acquired immune deficiency syndromes.

Reply to Sheng et al.

S. Oka, H. Gatanaga, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effectiveness of sitafloxacin monotherapy for quinolone-resistant rectal and urogenital Mycoplasma genitalium infections: a prospective cohort study

S. Oka, Yasuaki Yanagawa, Koji Watanabe, 2023, The Journal of antimicrobial chemotherapy.

Retroperitoneal fibrosis leading to extrahepatic portal vein obstruction.

Y. Yazaki, N. Matsuhashi, S. Ohnishi, 1994, Internal medicine.

Incidence and Risk Factors for Incident Syphilis among HIV-1-Infected Men Who Have Sex with Men in a Large Urban HIV Clinic in Tokyo, 2008−2015

H. Yazaki, S. Oka, S. Shibata, 2016, PloS one.

Antiretroviral therapy for treatment-naïve chronic HIV-1 infection with an axonal variant of Guillain-Barré syndrome positive for anti-ganglioside antibody: a case report.

S. Oka, K. Tsukada, H. Gatanaga, 2011, Internal medicine.

Author Correction: Glycerol phosphate shuttle enzyme GPD2 regulates macrophage inflammatory responses

J. Goedert, J. Margolick, C. Thio, 2019, Nature Immunology.

Association of demographics, HCV co‐infection, HIV‐1 subtypes and genetic clustering with late HIV diagnosis: a retrospective analysis from the Japanese Drug Resistance HIV‐1 Surveillance Network

S. Matsushita, M. Koga, T. Matano, 2023, Journal of the International AIDS Society.

A Quantitative System for Monitoring Blood-Circulating Viral Protein R of Human Immunodeficiency Virus-1 Detected a Possible Link with Pathogenic Indices.

S. Oka, M. Shimura, A. Matsunaga, 2019, AIDS research and human retroviruses.

Association of acute‐to‐chronic glycemic ratio and outcomes in patients with COVID‐19 and undiagnosed diabetes mellitus: A retrospective nationwide cohort study

K. Ueki, M. Ohsugi, H. Kajio, 2023, Journal of diabetes investigation.

Case Report: Acute Amebic Colitis Triggered by Colonoscopy: Exacerbation of Asymptomatic Chronic Infection with Entamoeba histolytica Accompanied by Dysbiosis

S. Oka, T. Nozaki, Yasuaki Yanagawa, 2019, American Journal of Tropical Medicine and Hygiene.

Combination of high-dose dexamethasone and antiretroviral therapy rapidly improved and induced long-term remission of HIV-related thrombocytopenic purpura

S. Oka, H. Gatanaga, K. Teruya, 2013, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

Serum thrombopoietin levels correlate with disease progression of AIDS.

S. Oka, T. Kato, H. Gatanaga, 1999, AIDS.

Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1

Hieu Tran Trung, S. Oka, Yasuaki Yanagawa, 2023, Microbiology spectrum.

EFdA, a reverse transcriptase inhibitor, potently blocks HIV-1 ex vivo infection of Langerhans cells within epithelium.

H. Mitsuya, K. Maeda, Y. Koyanagi, 2014, The Journal of investigative dermatology.

Various associations of aging and long-term HIV infection with different neurocognitive functions: detailed analysis of a Japanese nationwide multicenter study

H. Yazaki, S. Oka, Yasuaki Yanagawa, 2019, Journal of NeuroVirology.

Sitafloxacin- versus Moxifloxacin-based Sequential Treatment for Mycoplasma genitalium Infections: A Multicenter, Open-label, Randomized Controlled Trial (Preprint)

H. Gatanaga, M. Takano, M. Mitobe, 2023, JMIR Research Protocols.

Single Particle Tracking Confirms That Multivalent Tat Protein Transduction Domain-induced Heparan Sulfate Proteoglycan Cross-linkage Activates Rac1 for Internalization*

N. Ohuchi, H. Higuchi, Yasuhiro Suzuki, 2011, The Journal of Biological Chemistry.

A widely distributed HIV-1 provirus elimination assay to evaluate latency-reversing agents in vitro

Kwang Su Kim, S. Matsushita, H. Mitsuya, 2021, Cell reports methods.

A widely-distributed HIV-1 provirus elimination assay to evaluate 2 latency-reversing agents in vitro 3

Kosaku Kitagawa, S. Islam, S. Hattori, 2022 .

High incidence of renal stones among HIV-infected patients on ritonavir-boosted atazanavir than in those receiving other protease inhibitor-containing antiretroviral therapy.

S. Oka, Koji Watanabe, K. Tsukada, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-term weight gain after initiating combination antiretroviral therapy in treatment-naïve Asian people living with human immunodeficiency virus.

S. Oka, H. Gatanaga, Y. Kikuchi, 2021, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases.

Detection of HIV type 1 load by the Roche Cobas TaqMan assay in patients with viral loads previously undetectable by the Roche Cobas Amplicor Monitor.

H. Yazaki, S. Oka, K. Tsukada, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Electrocautery ablation of high-grade anal intraepithelial lesions: A protocol for a clinical trial

H. Gatanaga, M. Takano, T. Aoki, 2023, Medicine: Case Reports and Study Protocols.

Efficacy of Lactococcus lactis strain Plasma on clearance of anal HPV infection in men who have sex with men: A single-center, double-blinded, randomized placebo-controlled trial (CLEAR HPV study)

Koji Watanabe, H. Gatanaga, M. Takano, 2023, Medicine: Case Reports and Study Protocols.

Nucleos(t)ide reverse transcriptase inhibitor-sparing regimens in the era of standard 3-drug combination therapies for HIV-1 infection.

S. Oka, K. Tsukada, J. Masuda, 2020, Global health & medicine.

Virological outcomes of various first-line ART regimens in patients harbouring HIV-1 E157Q integrase polymorphism: a multicentre retrospective study.

M. Koga, A. Hachiya, Y. Yokomaku, 2023, The Journal of antimicrobial chemotherapy.

S. Oka, M. Kaku, A. Hachiya, 2010, Microbes and infection.

Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

S. Sarafianos, M. Matsuoka, S. Oka, 2009, Antiviral research.

Effect of unintended short-term 3.0 g/day amoxicillin and probenecid treatment for early syphilis on patients with HIV-1 infection

S. Oka, H. Gatanaga, Y. Kikuchi, 2023, Therapeutic advances in infectious disease.

Identification of viral protein R of human immunodeficiency virus-1 (HIV) and interleukin-6 as risk factors for malignancies in HIV-infected individuals: A cohort study

H. Gatanaga, Naokatsu Ando, Akihiro Matsunaga, 2024, PloS one.

Impact of Immune Reconstitution-induced Hepatic Flare on HBsAg Loss in HBV/HIV-1-Coinfected Patients.

T. Kawaguchi, S. Oka, M. Sugiyama, 2020, The Journal of infectious diseases.

Novel mutation of human DNA polymerase gamma associated with mitochondrial toxicity induced by anti-HIV treatment.

S. Oka, Takao Takahashi, H. Gatanaga, 2007, The Journal of infectious diseases.